Login / Signup

PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment.

Cheng-Yu ChangYi-Chun LaiYu-Feng WeiChung-Yu ChenShih-Chieh Chang
Published in: OncoTargets and therapy (2021)
For patients with metastatic NSCLC and EGFR mutations, PD-L1 expression is not uncommon, but no significant influence on clinical outcomes was observed in patients receiving standard initial treatment.
Keyphrases
  • small cell lung cancer
  • tyrosine kinase
  • epidermal growth factor receptor
  • advanced non small cell lung cancer
  • brain metastases